In:
Oncology, S. Karger AG, Vol. 79, No. 1-2 ( 2010), p. 93-97
Abstract:
〈 i 〉 Objective: 〈 /i 〉 To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin’s and non-Hodgkin’s lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim. 〈 i 〉 Methods: 〈 /i 〉 We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed. 〈 i 〉 Results: 〈 /i 〉 Fourteen (26%) patients with Hodgkin’s lymphoma and 40 (74%) patients with non-Hodgkin’s lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 µg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38). 〈 i 〉 Conclusion: 〈 /i 〉 Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2010
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
